Antitumor activity of lurbinectedin (PM01183) and doxorubicin in relapsed small-cell lung cancer: results from a phase I study.

Document types check

Please use this identifier to cite or link to this item: https://hdl.handle.net/20.500.12530/30265

Title:	Antitumor activity of lurbinectedin (PM01183) and doxorubicin in relapsed small-cell lung cancer: results from a phase I study.
Authors:	Calvo, E Moreno, V Flynn, M Holgado, E Olmedo, M E Lopez Criado, M P Kahatt, C Lopez-Vilariño, J A Siguero, M Fernandez-Teruel, C Cullell-Young, M Soto Matos-Pita, A Forster, M View more
Keywords:	PM01183 lurbinectedin phase I study small-cell lung cancer View more
Mesh:	Aged Antineoplastic Combined Chemotherapy Protocols Carbolines Carcinoma, Non-Small-Cell Lung Dose-Response Relationship, Drug Doxorubicin Female Heterocyclic Compounds, 4 or More Rings Humans Lung Neoplasms Male Middle Aged Neoplasm Recurrence, Local View more
Issue Date:	1-Oct-2017
Citation:	Ann. Oncol..2017 Oct;(28)10:2559-2566
Abstract:	Lurbinectedin (PM01183) has synergistic antitumor activity when combined with doxorubicin in mice with xenografted tumors. This phase I trial determined the recommended dose (RD) of doxorubicin (bolus) and PM01183 (1-h intravenous infusion) on day 1 every 3 weeks (q3wk), and obtained preliminary evidence of antitumor activity for this combination in small-cell lung cancer (SCLC).
PMID:	28961837
URI:	https://hdl.handle.net/20.500.12530/30265
Rights:	openAccess
Appears in Collections:	Fundaciones e Institutos de Investigación > IIS H. U. Ramón y Cajal > Artículos

Files in This Item:

File	Description	Size	Format
PMC5834091.pdf		334.42 kB	Adobe PDF	View/Open